News

EDX Medical – a clinical diagnostics company founded by Sir Christopher Evans, OBE – has announced the development of a new ‘super test’ for prostate cancer.

The test aims to speed up screening and diagnosis for the cancer, of which there are 55,000 new cases each year in the UK, and increase the adoption of personalised treatments for patients.

The multi-omics test assesses a variety of proteomic, transcriptomic, epigenetic, genetic and hereditary biomarkers, which are then cross-referenced with ‘additional phenotypic and symptom’ data by a proprietary AI model, according to the press release. By analysing this wide scope of biomarkers, the test has the potential to detect the presence of cancerous cells and the stage of cancer (if present), as well as the predicted speed of prognosis.

The test utilises both blood and urine samples, making it non-invasive for patients.

Founder and CSO of EDX Medical, Prof Sir Christopher Evans stated: “We have been working intensively in this area and are tremendously excited by what we believe is a truly game-changing test. Every indication thus far shows it will be the most accurate and sensitive screening test available, and will be transformative in tackling prostate cancer in men who may have no idea if anything is wrong with them.”

Adding to this, CEO Dr Mike Hudson said: “I’m confident that the EDX testing strategy will define a new standard for the early detection and characterisation of emergent prostate cancer and provide unique insights to guide optimal treatment selection.”

EDX Medical has filed a patent application for both the test and AI model with the European Patent Office. The company has stated that further clinical data will be validated before seeking approval from regulatory bodies in the both the US and UK.